“I would point out several important reasons why The 1:1 Diet is superior to these new weight-loss drugs. Firstly, weight loss is over twice as fast with The 1:1 Diet – eight weeks to lose an average of 1 ½ stone versus 20 weeks for Wegovy^1,2. Secondly, The 1:1 Diet is specifically formulated to provide all the nutrients you need, despite low calorie intake. These drugs, usually used by people who are already deficient in one or more nutrients, cause you to eat very few calories, making it difficult to get adequate nutrition. Thirdly, (and likely because of inadequate nutrition) almost 40% of weight loss on Wegovy is lean tissue (not fat loss), so they cause a substantially lower percent fat loss than our diet^3,4. Finally, two thirds of weight loss is regained within a year of stopping these drugs, whereas a four-year study of The 1:1 Diet showed 100% of weight loss can be maintained^2,5.”

References:

1. Christensen P, Meinert Larsen T, Westerterp-Plantenga M, et al. Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018 Dec;20(12):2840-2851.
2. John P. H. Wilding, Rachel L. Batterham, Melanie Davies, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism. 24(8), 2022. 1553-64.
3. O’Neil PM, Rubino DM. Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgrad Med. 2022 Jan;134(sup1):28-36.
4. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021 May 3;5(Suppl 1):A16–7.
5. Christensen P, Henriksen M, Bartels EM, et al. Long-term weight-loss maintenance in obese patients with knee osteoarthritis: a randomized trial. Am J Clin Nutr. 2017 Sep;106(3):755-763.